RESUMEN
Overexpression of the brain and acute leukemia, cytoplasmic (BAALC) gene is implicated in myeloid leukemogenesis and associated with poor outcome in both acute myeloid leukemia (AML) and acute lymphoblastic leukemia patients. Additionally, high BAALC expression occurs in glioblastoma, melanoma, and childhood gastrointestinal stroma tumors, suggesting an oncogenic role for BAALC. However, the mechanisms underlying the deregulated expression are unknown. We hypothesized that a common heritable genetic feature located in cis might account for overexpression of BAALC in an allele-specific manner. By sequencing the genomic region of BAALC we identified nine informative single nucleotide polymorphisms (SNPs) and tested them for a possible association with BAALC expression levels. We show that BAALC overexpression occurs in the presence of the T allele of SNP rs62527607[GT], which creates a binding site for the activating RUNX1 transcription factor in the BAALC promoter region. The mechanism is demonstrated experimentally in vitro using luciferase reporter assays and electrophoretic mobility shift assay (EMSA) analysis. The association of high BAALC expression with the T allele and its correlations with RUNX1 expresser status are shown in vivo in a test set (n = 253) and validation set (n = 105) of samples from cytogenetically normal AML patients from different populations. Thus, we identify a heritable genomic feature predisposing to overexpression of an oncogene, thereby possibly leading to enhanced AML leukemogenesis. Our findings further suggest that genomic variants might become useful tools in the practice of personalized medicine.
Asunto(s)
Leucemia Mieloide Aguda/genética , Proteínas de Neoplasias/genética , Polimorfismo de Nucleótido Simple , Adulto , Anciano , Alelos , Sitios de Unión , Subunidad alfa 2 del Factor de Unión al Sitio Principal/genética , Femenino , Humanos , Masculino , Persona de Mediana Edad , Regiones Promotoras GenéticasRESUMEN
High BAALC expression levels are associated with poor outcome in cytogenetically normal acute myeloid leukemia (CN-AML) patients. Recently, miR-3151 was discovered in intron 1 of BAALC. To evaluate the prognostic significance of miR-3151 expression levels and to gain insight into the biologic and prognostic interplay between miR-3151 and its host, miR-3151 and BAALC expression were measured in pretreatment blood of 179 CN-AML patients. Gene-expression profiling and miRNA-expression profiling were performed using microarrays. High miR-3151 expression was associated with shorter disease-free and overall survival, whereas high BAALC expression predicted failure of complete remission and shorter overall survival. Patients exhibiting high expression of both miR-3151 and BAALC had worse outcome than patients expressing low levels of either gene or both genes. In gene-expression profiling, high miR-3151 expressers showed down-regulation of genes involved in transcriptional regulation, posttranslational modification, and cancer pathways. Two genes, FBXL20 and USP40, were validated as direct miR-3151 targets. The results of the present study show that high expression of miR-3151 is an independent prognosticator for poor outcome in CN-AML and affects different outcome end points than its host gene, BAALC. The combination of both markers identified a patient subset with the poorest outcome. This interplay between an intronic miR and its host may have important biologic implications.
Asunto(s)
Leucemia Mieloide Aguda/genética , MicroARNs/genética , Proteínas de Neoplasias/genética , ARN Neoplásico/genética , Anciano , Anciano de 80 o más Años , Análisis Citogenético , Supervivencia sin Enfermedad , Proteínas F-Box/genética , Femenino , Expresión Génica , Humanos , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Pronóstico , Ubiquitina Tiolesterasa/genéticaRESUMEN
The amnionless gene, Amn, on mouse chromosome 12 encodes a type I transmembrane protein that is expressed in the extraembryonic visceral layer during gastrulation. Mice homozygous with respect to the amn mutation generated by a transgene insertion have no amnion. The embryos are severely compromised, surviving to the tenth day of gestation but seem to lack the mesodermal layers that normally produce the trunk. The Amn protein has one transmembrane domain separating a larger, N-terminal extracellular region and a smaller, C-terminal cytoplasmic region. The extracellular region harbors a cysteine-rich domain resembling those occurring in Chordin, found in Xenopus laevis embryos, and Sog, found in Drosophila melanogaster. As these cysteine-rich domains bind bone morphogenetic proteins (Bmps), it has been speculated that the cysteine-rich domain in Amn also binds Bmps. We show that homozygous mutations affecting exons 1-4 of human AMN lead to selective malabsorption of vitamin B12 (a phenotype associated with megaloblastic anemia 1, MGA1; OMIM 261100; refs. 5,6) in otherwise normal individuals, suggesting that the 5' end of AMN is dispensable for embryonic development but necessary for absorption of vitamin B12. When the 5' end of AMN is truncated by mutations, translation is initiated from alternative downstream start codons.
Asunto(s)
Anemia Megaloblástica/genética , Proteínas de la Membrana/genética , Proteínas de la Membrana/fisiología , Mutación , Amnios/anomalías , Animales , Secuencia de Bases , ADN/genética , Análisis Mutacional de ADN , Femenino , Gástrula , Genes Recesivos , Humanos , Masculino , Ratones , Datos de Secuencia Molecular , LinajeRESUMEN
BACKGROUND & AIMS: Expression of the netrin-1 dependence receptor UNC5C is reduced in many colorectal tumors; mice with the UNC5C mutations have increased progression of intestinal tumors. We investigated whether specific variants in UNC5C increase risk of colorectal cancer (CRC). METHODS: We analyzed the sequence of UNC5C in blood samples from 1801 patients with CRC and 4152 controls from 3 cohorts (France, United States, and Finland). Almost all cases from France and the United States had familial CRC; of the Finnish cases, 92 of 984 were familial. We analyzed whether CRC segregates with the UNC5C variant A628K in 3 families with histories of CRC. We also performed haplotype analysis to determine the origin of this variant. RESULTS: Of 817 patients with familial CRC, 14 had 1 of 4 different, unreported missense variants in UNC5C. The variants p.Asp353Asn (encodes D353N), p.Arg603Cys (encodes R603C), and p.Gln630Glu (encodes Q630E) did not occur significantly more often in cases than controls. The variant p.Ala628Lys (A628K) was detected in 3 families in the French cohort (odds ratio, 8.8; Wald's 95% confidence interval, 1.47-52.93; P = .03) and in 2 families in the US cohort (odds ratio, 1.9; P = .6) but was not detected in the Finnish cohort; UNC5C A628K segregated with CRC in families. Three families with A628K had a 109-kilobase identical haplotype that spanned most of UNC5C, indicating recent origin of this variant in white subjects (14 generations; 95% confidence interval, 6-36 generations). Transfection of HEK293T cells with UNC5C-A628K significantly reduced apoptosis compared with wild-type UNC5C, measured in an assay of active caspase-3. CONCLUSIONS: Inherited mutations in UNC5C prevent apoptosis and increase risk of CRC.
Asunto(s)
Poliposis Adenomatosa del Colon/genética , Apoptosis/genética , Mutación Missense/genética , Receptores de Superficie Celular/genética , Poliposis Adenomatosa del Colon/sangre , Estudios de Casos y Controles , Estudios de Cohortes , Análisis Mutacional de ADN , Predisposición Genética a la Enfermedad , Haplotipos/genética , Humanos , Immunoblotting , Inmunohistoquímica , Receptores de Netrina , Linaje , Reacción en Cadena de la Polimerasa , Receptores de Superficie Celular/sangre , Factores de RiesgoRESUMEN
We report a rare case of juvenile cobalamin deficiency who presented at the age of 17 years. He was underweight and had skin changes, normocytic anemia, and autonomic dysfunction, which led to adynamic ileus and acute postrenal failure. The expected macrocytosis was masked by an underlying alpha-thalassemia trait. The patient had an excellent response to parenteral cobalamin treatment.
Asunto(s)
Enfermedades del Sistema Nervioso Autónomo/etiología , Exantema/etiología , Deficiencia de Vitamina B 12/complicaciones , Vitamina B 12/sangre , Adolescente , Criptorquidismo/complicaciones , Gastrosquisis/complicaciones , Humanos , Hidronefrosis/complicaciones , Hidronefrosis/congénito , Masculino , Riñón Displástico Multiquístico/complicaciones , Obstrucción Ureteral/complicaciones , Obstrucción Ureteral/congénito , Deficiencia de Vitamina B 12/fisiopatologíaRESUMEN
Fifty years have passed since the description of juvenile selective malabsorption of cobalamin (Cbl). Quality of life improvements have dramatically reduced the incidence of parasite-induced or nutritional Cbl deficiency. Consequently, inherited defects have become a leading cause of Cbl deficiency in children, which is not always expressed as anemia. Unfortunately, the gold standard for clinical diagnosis, the Schilling test, has increasingly become unavailable, and replacement tests are only in their infancy. Genetic testing is complicated by genetic heterogeneity and differential diagnosis. This review documents the history, research, and advances in genetics that have elucidated the causes of juvenile Cbl malabsorption. Genetic research has unearthed many cases in the past decade, mostly in Europe and North America, often among immigrants from the Middle East or North Africa. Lack of suitable clinical testing potentially leaves many patients inadequately diagnosed. The consequences of suboptimal Cbl levels for neurological development are well documented. By raising awareness, we wish to push for fast track development of better clinical tools and suitable genetic testing. Clinical awareness must include attention to ethnicity, a sensitive topic but effective for fast diagnosis. The treatment with monthly parenteral Cbl for life offers a simple and cost-effective solution once proper diagnosis is made.
Asunto(s)
Pruebas Genéticas , Síndromes de Malabsorción/complicaciones , Síndromes de Malabsorción/genética , Deficiencia de Vitamina B 12/etiología , Deficiencia de Vitamina B 12/genética , Vitamina B 12/metabolismo , Análisis Mutacional de ADN , Humanos , Síndromes de Malabsorción/diagnóstico , Síndromes de Malabsorción/terapia , Prueba de Schilling , Deficiencia de Vitamina B 12/diagnóstico , Deficiencia de Vitamina B 12/terapiaRESUMEN
Nuclear factor (NF)-kappaB is a positive regulator of tumour development and progression, but how it functions in normal cells leading to oncogenesis is not clear. As cellular senescence has proven to be an intrinsic tumour suppressor mechanism that cells must overcome to establish deregulated growth, we used primary fibroblasts to follow NF-kappaB function in cells transitioning from senescence to subsequent immortalization. Our findings show that RelA/p65(-/-) murine fibroblasts immortalize at considerably faster rates than RelA/p65(+/+) cells. The ability of RelA/p65(-/-) fibroblasts to escape senescence earlier is due to their genomic instability, characterized by high frequencies of DNA mutations, gene deletions and gross chromosomal translocations. This increase in genomic instability is closely related to a compromised DNA repair that occurs in both murine RelA/p65(-/-) fibroblasts and tissues. Significantly, these results can also be duplicated in human fibroblasts lacking NF-kappaB. Altogether, our findings present a fresh perspective on the role of NF-kappaB as a tumour suppressor, which acts in pre-neoplastic cells to maintain cellular senescence by promoting DNA repair and genomic stability.
Asunto(s)
Senescencia Celular , Reparación del ADN , Inestabilidad Genómica , Factor de Transcripción ReIA/metabolismo , Células 3T3 , Animales , Línea Celular , ADN/genética , Fibroblastos/metabolismo , Eliminación de Gen , Peróxido de Hidrógeno/química , Ratones , Mutación , FN-kappa B/metabolismo , Translocación GenéticaRESUMEN
The genetic component of colorectal cancer (CRC) predisposition has been only partially explained. We recently suggested that a subtle decrease in the expression of one allele of the TGFBR1 gene was a heritable quantitative trait predisposing to CRC. Here, we refined the measurements of allele-specific expression (ASE) of TGFBR1 in a population-based series of CRC patients and controls. Five single-nucleotide polymorphisms (SNPs) in the 3'-untranslated region of the gene were genotyped and used for ASE determination by pyrosequencing. After eliminating non-informative samples and samples with RNA of insufficient quality 109 cases and 125 controls were studied. Allelic ratios ranged between 0.74 and 1.69 without evidence of bimodality or cutoff points for 'ASE' versus 'non-ASE'. Treating ASE as a continuous variable, cases had non-significantly different values than controls (P = 0.081 when comparing means by permutation test). However, cases had significantly higher ASE values when comparing medians by permutation test (P = 0.0027) and when using Wilcoxon test (P = 0.0094). We conclude that with the present-day technology, ASE differences between individuals and between cases and controls are too subtle to be used to assess CRC risk. More advanced technology is expected to resolve this issue as well as the low informativity caused by the limited heterozygosity of transcribed SNPs.
Asunto(s)
Neoplasias del Colon/genética , Polimorfismo de Nucleótido Simple , Proteínas Serina-Treonina Quinasas/genética , Receptores de Factores de Crecimiento Transformadores beta/genética , Adulto , Anciano , Anciano de 80 o más Años , Alelos , Femenino , Regulación Neoplásica de la Expresión Génica , Humanos , Masculino , Persona de Mediana Edad , Carácter Cuantitativo Heredable , Receptor Tipo I de Factor de Crecimiento Transformador betaAsunto(s)
Proteínas Asociadas a Resistencia a Múltiples Medicamentos/genética , Mutación , Vitamina B 12/metabolismo , Animales , Transporte Biológico , Humanos , Proteínas Asociadas a Resistencia a Múltiples Medicamentos/metabolismo , Deficiencia de Vitamina B 12/genética , Deficiencia de Vitamina B 12/metabolismoRESUMEN
Molecular profiling may lead to a better understanding of a disease. This knowledge is especially important in malignancies, where multiple alterations are required during the progression from premalignant to malignant stages. Such information can be useful for the development of novel biomarkers that allow the prediction of a clinical course, response to treatment or early detection. Molecular data is also utilized to develop targeted therapies. Moreover, gene defects identified in profiling studies will help to understand the molecular pathways disrupted in the disease. This review provides an overview of molecular profiling approaches in chronic lymphocytic leukaemia (CLL). We will describe our current understanding of genetic alterations in CLL, the use of familial CLL for the identification of predisposing mutations, and the search for epigenetic alterations in CLL.
Asunto(s)
Predisposición Genética a la Enfermedad , Leucemia Linfocítica Crónica de Células B/genética , Proteínas Reguladoras de la Apoptosis/genética , Proteínas Quinasas Dependientes de Calcio-Calmodulina/genética , Proteínas Quinasas Asociadas a Muerte Celular , Epigénesis Genética , Perfilación de la Expresión Génica/métodos , Silenciador del Gen , Genómica , HumanosAsunto(s)
Factor Intrinseco/genética , Mutación , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Deficiencia de Vitamina B 12/genética , Preescolar , Femenino , Humanos , Factor Intrinseco/deficiencia , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicaciones , Deficiencia de Vitamina B 12/complicacionesRESUMEN
Transcripts of the Brain and Acute Leukemia, Cytoplasmic (BAALC) gene are expressed in human neuroectodermal tissues and in CD34-positive bone marrow cells. High transcript levels occur in leukemic blasts from some patients with acute myeloid leukemia (AML), where high expression is an independent marker of poor prognosis. To gain insight into the hitherto unknown function of BAALC/Baalc, we studied its protein expression in embryonic and adult mouse tissue by immunohistochemical analysis. Baalc protein was mainly expressed in developing and mature muscle cells (cardiac, skeletal, and smooth) beginning on day E9 (heart). Signal was seen in the pre-muscle mesodermal cells of the dermatomyotome regions, and the derivatives of the lateral plate and intermediate mesoderm such as smooth muscle wall of the esophagus, stomach, the gut tube, bronchi, small blood vessels, and urinary bladder. This pattern continued through the late embryonic stages into adulthood. Baalc appeared to localize in the cytoplasm, adjacent to the cell membrane. This is distinctly observed in adult skeletal muscle cells. Baalc co-localized with known muscle-associated proteins but not with neural crest or neuronal markers. Scattered expression in adult bone marrow hematopoietic cells and weak expression in the brain neuropil also occurred. In conclusion, BAALC/Baalc is a marker of the mesodermal lineage, especially muscle.
Asunto(s)
Cromosomas Humanos Par 8 , Mesodermo/fisiología , Músculo Esquelético/fisiología , Proteínas de Neoplasias/genética , Animales , Línea Celular , Mapeo Cromosómico , Regulación del Desarrollo de la Expresión Génica , Humanos , Leucemia/genética , Ratones , Ratones Endogámicos BALB C , Músculo Esquelético/embriología , Músculo Esquelético/crecimiento & desarrolloAsunto(s)
Factor Intrinseco/genética , Mutación , Deficiencia de Vitamina B 12/genética , Adolescente , Humanos , MasculinoRESUMEN
OBJECTIVE: Juvenile megaloblastic anemia is a rare and often hereditary disorder of cobalamin absorption, transport or intracellular metabolism. Several syndromes present with megaloblastic anemia such as congenital megaloblastic anemia due to intrinsic factor defect and juvenile megaloblastic anemia with proteinuria due to defects in the cubilin or the amnionless protein. METHODS: We identified a large kindred with juvenile megaloblastic anemia. Four genes, GIF, CUBN, TCN1, and TCN2, was previously excluded from being responsible for the syndrome of this family who was discovered in Irbid, Jordan, during the year 1999. At that time, the amnionless (AMN) gene was not yet known to implicate in megaloblastic anemia. In this study, we screened the AMN for mutations in the Ohio State University, Iowa, United States of America. In addition, follow-up testing was carried out in the University of Iowa in 2004. RESULTS: We identified a homozygous splice site mutation in the patients. This mutation was previously detected in families from Turkey and Tunisia. It is suspected to be a founder mutation of Middle Eastern origin. CONCLUSION: Molecular testing for this specific mutation in cases of Middle Eastern origin is a valuable tool for presymptomatic diagnosis, carrier identification and perhaps prenatal diagnosis.
Asunto(s)
Anemia Megaloblástica/genética , Síndromes de Malabsorción/genética , Mutación/genética , Proteínas/genética , Sitios de Empalme de ARN/genética , Deficiencia de Vitamina B 12/genética , Femenino , Humanos , Jordania , Masculino , Proteínas de la Membrana , LinajeRESUMEN
OBJECTIVE: The gene BAALC (Brain And Acute Leukemia, Cytoplasmic), a novel molecular marker involved in leukemia, is highly expressed in a subset of patients with acute leukemia and predictive of clinical outcome in patients with acute myeloid leukemia and normal karyotype. The role of BAALC in hematopoiesis and leukemogenesis is unknown. MATERIAL AND METHODS: We used real-time RT-PCR to show that BAALC is strongly expressed in CD34(+) cells from the bone marrow and blood and only weakly expressed in total normal bone marrow and blood cells. RESULTS: Expression analyses of FACSorted cells revealed high BAALC transcript levels in CD34(+) bone marrow cells including CD34(+)/CD38(-), CD34(+)/CD33(+), as well as CD34(+)/CD19(+)/CD10(+), CD34(+)/CD7(+), and CD34(+)/CD71(+)/CD45(-) cell fractions. Expression was significantly lower in all CD34(-) fractions. In vitro differentiation of CD34(+) bone marrow cells showed downregulation of BAALC and CD34 transcripts as early as day 4 in suspension cultures supplemented with lineage-specific cytokines (G-CSF, M-CSF, or EPO). In cultures with only lineage-unspecific cytokines (IL-3, SCF, GM-CSF), BAALC transcripts persisted up to day 20, while CD34 transcripts disappeared earlier. These observations suggest that expression of BAALC is stage specific. CONCLUSIONS: BAALC expression is restricted to progenitor cells, and downregulation of BAALC occurs with cell differentiation. We postulate that BAALC represents a novel marker of an early progenitor cell common to the myeloid, lymphoid, and erythroid pathways.
Asunto(s)
Células Madre Hematopoyéticas/química , Proteínas de Neoplasias/análisis , Proteínas de Neoplasias/fisiología , Antígenos CD34/análisis , Biomarcadores , Células de la Médula Ósea/química , Células de la Médula Ósea/citología , Diferenciación Celular , Humanos , Inmunohistoquímica , Proteínas de Neoplasias/genéticaRESUMEN
Selective intestinal malabsorption of vitamin B(12) causing juvenile megaloblastic anemia (MGA; MIM# 261100) is a recessively inherited disorder that is believed to be rare except for notable clusters of cases in Finland, Norway, and the Eastern Mediterranean region. The disease can be caused by mutations in either the cubilin (CUBN; MGA1; MIM# 602997) or the amnionless (AMN; MIM# 605799) gene. To explain the peculiar geographical distribution, we hypothesized that mutations in one of the genes would mainly be responsible for the disease in Scandinavia, and mutations in the other gene in the Mediterranean region. We studied 42 sibships and found all cases in Finland to be due to CUBN (three different mutations) and all cases in Norway to be due to AMN (two different mutations), while in Turkey, Israel, and Saudi Arabia, there were two different AMN mutations and three different CUBN mutations. Haplotype evidence excluded both CUBN and AMN conclusively in five families and tentatively in three families, suggesting the presence of at least one more gene locus that can cause MGA. We conclude that the Scandinavian cases are typical examples of enrichment by founder effects, while in the Mediterranean region high degrees of consanguinity expose rare mutations in both genes. We suggest that in both regions, physician awareness of this disease causes it to be more readily diagnosed than elsewhere; thus, it may well be more common worldwide than previously thought.
Asunto(s)
Anemia Megaloblástica/genética , Efecto Fundador , Mutación , Deficiencia de Vitamina B 12/genética , Consanguinidad , Análisis Mutacional de ADN , Femenino , Haplotipos , Humanos , Absorción Intestinal , Masculino , Proteínas de la Membrana , Medio Oriente , Linaje , Proteínas/genética , Receptores de Superficie Celular/genética , Países Escandinavos y Nórdicos , Deficiencia de Vitamina B 12/diagnósticoAsunto(s)
Factor Intrinseco/genética , Mutación , Deficiencia de Vitamina B 12/genética , Población Negra/genética , Niño , Femenino , Efecto Fundador , Humanos , Masculino , LinajeRESUMEN
Juvenile vitamin B(12) or cobalamin (Cbl) deficiency is notoriously difficult to explain due to numerous acquired and inherited causes. The consequences of insufficient Cbl are megaloblastic anemia, nutrient malabsorption, and neurological problems. The treatment is straightforward with parenteral Cbl supplementation that resolves most health issues without an urgent need to clarify their cause. Aside from being clinically unsatisfying, failing to elucidate the basis of Cbl deficiency means important information regarding recurrence risk is not available to the individual if the cause is contagious or inherited. Acquired causes have largely disappeared in the Modern World because they were mostly due to parasites or malnutrition. Today, perhaps the most common causes of juvenile Cbl deficiency are Imerslund-Gräsbeck syndrome and inherited intrinsic factor deficiency (IFD). Three genes are involved and genetic testing is complicated and not widely available. We used self-identified ancestry to accelerate and confirm the genetic diagnosis of IFD in three families of Chaldean origin. A founder mutation limited to Chaldeans from Iraq in the intrinsic factor gene GIF was identified as the cause. World events reshape the genetic structure of populations and inherited diseases in many ways. In this case, all the patients were diagnosed in the USA among recent immigrants from a single region. While IFD itself is not restricted to one kind of people, certain mutations are limited in their range but migrations relocate them along with their host population. As a result, self-identified ancestry as a stratifying characteristic should perhaps be considered in diagnostic strategies for rare genetic disorders.
RESUMEN
We previously reported a rare germline variant (c.1-6531) that resulted in allele-specific expression (ASE) of death-associated protein kinase 1 (DAPK1) and predisposition to chronic lymphocytic leukemia (CLL). We investigated a cohort of CLL patients lacking this mutation for the presence of ASE of DAPK1. We developed a novel strategy that combines single-nucleotide primer extension (SNuPE) with MALDI-TOF mass spectrometry, and detected germline DAPK1 ASE in 17 out of 120 (14.2%) CLL patients associated with a trend towards younger age at diagnosis. ASE was absent in 63 healthy controls. Germline cells of CLL patients with ASE showed increased levels of DNA methylation in the promoter region, however, neither genetic nor further epigenetic aberrations could be identified in the DAPK1 5' upstream regulatory region, within distinct exons or in the 3'-UTR. We identified B-lymphoid malignancy related cell line models harboring allelic imbalance and found that allele-specific methylation in DAPK1 is associated with ASE. Our data indicate that ASE at the DAPK1 gene locus is a recurrent event, mediated by epigenetic mechanisms and potentially predisposing to CLL.